Published in Cancer Res on October 15, 2004
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A (2009) 2.61
Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature (2015) 2.20
Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell (2010) 1.95
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo. PLoS Genet (2006) 1.66
Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol (2005) 1.54
p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop. Mol Cell Biol (2006) 1.26
Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53. Nucleic Acids Res (2007) 1.23
Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nat Commun (2013) 1.19
Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia (2008) 1.18
Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem (2010) 1.18
Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A (2014) 1.09
Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep (2012) 1.03
p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. Arch Biochem Biophys (2011) 1.02
More targets, more pathways and more clues for mutant p53. Oncogenesis (2013) 1.00
Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl. Genes Cancer (2012) 0.99
p53 induces distinct epigenetic states at its direct target promoters. BMC Genomics (2008) 0.96
Mapping the p53 transcriptome universe using p53 natural polymorphs. Cell Death Differ (2013) 0.95
Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. J Biol Chem (2007) 0.94
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Curr Genomics (2008) 0.92
Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity. Cell Cycle (2012) 0.91
Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem Biophys Res Commun (2012) 0.89
Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther (2012) 0.89
Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter. Oncotarget (2016) 0.85
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. PLoS One (2015) 0.85
Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Arch Biochem Biophys (2011) 0.84
MIG-7 and phosphorylated prohibitin coordinately regulate lung cancer invasion/metastasis. Oncotarget (2015) 0.83
Identification of signaling pathways mediating cell cycle arrest and apoptosis induced by Porphyromonas gingivalis in human trophoblasts. Infect Immun (2012) 0.83
Functional Genomics and a New Era in Radiation Biology and Oncology. Bioscience (2008) 0.81
Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer. Front Oncol (2015) 0.79
Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. Sci Rep (2015) 0.78
The Contrived Mutant p53 Oncogene - Beyond Loss of Functions. Front Oncol (2015) 0.77
Racial disparity in metabolic regulation of cancer. Front Biosci (Landmark Ed) (2017) 0.76
Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice. PLoS One (2015) 0.75
Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication. J Clin Invest (2017) 0.75
Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells. Mol Oncol (2017) 0.75
A model of molecular interactions on short oligonucleotide microarrays. Nat Biotechnol (2003) 9.98
Retracted FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest (2011) 2.44
Ethanol-responsive brain region expression networks: implications for behavioral responses to acute ethanol in DBA/2J versus C57BL/6J mice. J Neurosci (2005) 2.05
Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol (2005) 1.54
The mGluR5 antagonist MPEP selectively inhibits the onset and maintenance of ethanol self-administration in C57BL/6J mice. Psychopharmacology (Berl) (2005) 1.51
Identifying gene regulatory networks in schizophrenia. Neuroimage (2010) 1.34
A new algorithm for analysis of oligonucleotide arrays: application to expression profiling in mouse brain regions. J Mol Biol (2002) 1.33
Overlapping microarray profiles of dentate gyrus gene expression during development- and epilepsy-associated neurogenesis and axon outgrowth. J Neurosci (2003) 1.33
Characterization of the ethanol-deprivation effect in substrains of C57BL/6 mice. Alcohol (2006) 1.33
Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene (2004) 1.29
Genetic dissection of acute ethanol responsive gene networks in prefrontal cortex: functional and mechanistic implications. PLoS One (2012) 1.29
Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics. Am J Med Genet B Neuropsychiatr Genet (2004) 1.21
ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res (2013) 1.15
HCV genotype distribution and possible transmission risks in Lahore, Pakistan. World J Gastroenterol (2010) 1.14
Genomic analysis of individual differences in ethanol drinking: evidence for non-genetic factors in C57BL/6 mice. PLoS One (2011) 1.08
SScore: an R package for detecting differential gene expression without gene expression summaries. Bioinformatics (2006) 1.04
ERGR: An ethanol-related gene resource. Nucleic Acids Res (2008) 1.04
Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis (2011) 1.03
p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. Arch Biochem Biophys (2011) 1.02
Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers. Virol J (2011) 0.99
Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl. Genes Cancer (2012) 0.99
A transposon in Comt generates mRNA variants and causes widespread expression and behavioral differences among mice. PLoS One (2010) 0.98
Systems genetic analysis of the effects of iron deficiency in mouse brain. Neurogenetics (2012) 0.98
A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol (2011) 0.96
Whole brain and brain regional coexpression network interactions associated with predisposition to alcohol consumption. PLoS One (2013) 0.96
DNA microarray and proteomic strategies for understanding alcohol action. Alcohol Clin Exp Res (2006) 0.94
Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants. Oncogene (2002) 0.93
Application of the S-score algorithm for analysis of oligonucleotide microarrays. Methods (2003) 0.93
Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior. Brain Struct Funct (2013) 0.92
Characterization of pharmacological and behavioral differences to nicotine in C57Bl/6 and DBA/2 mice. Neuropharmacology (2009) 0.92
Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis. Virol J (2011) 0.92
Empirical validation of the S-Score algorithm in the analysis of gene expression data. BMC Bioinformatics (2006) 0.90
Using expression genetics to study the neurobiology of ethanol and alcoholism. Int Rev Neurobiol (2010) 0.90
The neuropeptide galanin and variants in the GalR1 gene are associated with nicotine dependence. Neuropsychopharmacology (2011) 0.90
Pharmacogenomic analysis of mechanisms mediating ethanol regulation of dopamine beta-hydroxylase. J Biol Chem (2003) 0.90
NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b. Virol J (2011) 0.89
Genetic analysis of the neurosteroid deoxycorticosterone and its relation to alcohol phenotypes: identification of QTLs and downstream gene regulation. PLoS One (2011) 0.89
Real-time polymerase chain reaction quantitation of relative expression of genes modulated by p53 using SYBR Green I. Methods Mol Biol (2003) 0.89
MDM2 controls the timely expression of cyclin A to regulate the cell cycle. Mol Cancer Res (2009) 0.89
Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem Biophys Res Commun (2012) 0.89
p53: its mutations and their impact on transcription. Subcell Biochem (2014) 0.89
The growth arrest function of the human oncoprotein mouse double minute-2 is disabled by downstream mutation in cancer cells. Cancer Res (2005) 0.88
Multi-species data integration and gene ranking enrich significant results in an alcoholism genome-wide association study. BMC Genomics (2012) 0.88
Inhibition of core gene of HCV 3a genotype using synthetic and vector derived siRNAs. Virol J (2010) 0.88
RNAi as a new therapeutic strategy against HCV. Biotechnol Adv (2009) 0.87
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J (2011) 0.85
Progress in using mouse inbred strains, consomics, and mutants to identify genes related to stress, anxiety, and alcohol phenotypes. Alcohol Clin Exp Res (2006) 0.84
Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Arch Biochem Biophys (2011) 0.84
HDM2-binding partners: interaction with translation elongation factor EF1alpha. J Proteome Res (2007) 0.84
Ethanol modulation of gene networks: implications for alcoholism. Neurobiol Dis (2011) 0.83
Using in vitro models for expression profiling studies on ethanol and drugs of abuse. Addict Biol (2005) 0.83
Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells. Genes Cancer (2011) 0.83
Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol (2010) 0.83
Association of laboratory parameters with viral factors in patients with hepatitis C. Virol J (2011) 0.83
Epistatic and environmental control of genome-wide gene expression. Twin Res Hum Genet (2005) 0.83
Fyn-dependent gene networks in acute ethanol sensitivity. PLoS One (2013) 0.83
Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV. Virol J (2011) 0.82
Role of adrenal glucocorticoid signaling in prefrontal cortex gene expression and acute behavioral responses to ethanol. Alcohol Clin Exp Res (2012) 0.82
Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites. Oncotarget (2014) 0.81
Identification of genes potentially regulated by human polynucleotide phosphorylase (hPNPase old-35) using melanoma as a model. PLoS One (2013) 0.81
Use of the DNA fiber spreading technique to detect the effects of mutant p53 on DNA replication. Methods Mol Biol (2013) 0.81
Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. Am J Surg Pathol (2015) 0.81
Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis. Arch Virol (2010) 0.81
Alcohol effects on central nervous system gene expression in genetic animal models. Alcohol Clin Exp Res (2005) 0.81
Mutant p53 in cell adhesion and motility. Methods Mol Biol (2013) 0.80
Inhibition of full length hepatitis C virus particles of 1a genotype through small interference RNA. Virol J (2011) 0.80
Flow cytometric analysis of MDM2-mediated growth arrest. Methods Mol Biol (2003) 0.80
HCV genotype-specific correlation with serum markers: higher predictability for genotype 4a. Virol J (2011) 0.80
Complex genetics of interactions of alcohol and CNS function and behavior. Alcohol Clin Exp Res (2005) 0.80
Lung cancer stem cells, p53 mutations and MDM2. Subcell Biochem (2014) 0.79
Microarray analysis of ethanol-induced changes in gene expression. Methods Mol Biol (2008) 0.79
Claudin-1 required for HCV virus entry has high potential for phosphorylation and O-glycosylation. Virol J (2011) 0.79
Expression, covariation, and genetic regulation of miRNA Biogenesis genes in brain supports their role in addiction, psychiatric disorders, and disease. Front Genet (2013) 0.79
HCV entry receptors as potential targets for siRNA-based inhibition of HCV. Genet Vaccines Ther (2011) 0.79
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray. J Transl Med (2012) 0.78
The human oncoprotein MDM2 induces replication stress eliciting early intra-S-phase checkpoint response and inhibition of DNA replication origin firing. Nucleic Acids Res (2013) 0.78
Identifying gene networks underlying the neurobiology of ethanol and alcoholism. Alcohol Res (2012) 0.78
Transactivation and transrepression studies with p53. Methods Mol Biol (2003) 0.77
Anti-apoptotic effect of HCV core gene of genotype 3a in Huh-7 cell line. Virol J (2011) 0.77
Down-regulation of IRES containing 5'UTR of HCV genotype 3a using siRNAs. Virol J (2011) 0.77
Stable Huh-7 cell lines expressing non-structural proteins of genotype 1a of hepatitis C virus. J Virol Methods (2013) 0.77
Serine 204 phosphorylation and O-β-GlcNAC interplay of IGFBP-6 as therapeutic indicator to regulate IGF-II functions in viral mediated hepatocellular carcinoma. Virol J (2011) 0.77
Hepatitis C virus p7: molecular function and importance in hepatitis C virus life cycle and potential antiviral target. Liver Int (2011) 0.76